The emerging roles of HDACs and their therapeutic implications in cancer

• Published in: European journal of pharmacology Vol. 931; p. 175216
• Main Authors: Hai, Rihan, Yang, Deyi, Zheng, Feifei, Wang, Weiqin, Han, Xing, Bode, Ann M., Luo, Xiangjian
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 15.09.2022
• Subjects: Acetylation; Cancer; Epigenetic modification; HDACis; HDACs; HDACis; HDACs; Acetylation; Epigenetic modification; Cancer
• ISSN: 0014-2999; 1879-0712
• DOI: 10.1016/j.ejphar.2022.175216

Deregulation of protein post-translational modifications is intensively involved in the etiology of diseases, including degenerative diseases, inflammatory injuries, and cancers. Acetylation is one of the most common post-translational modifications of proteins, and the acetylation levels are controlled by two mutually antagonistic enzyme families, histone acetyl transferases (HATs) and histone deacetylases (HDACs). HATs loosen the chromatin structure by neutralizing the positive charge of lysine residues of histones; whereas HDACs deacetylate certain histones, thus inhibiting gene transcription. Compared with HATs, HDACs have been more intensively studied, particularly regarding their clinical significance. HDACs extensively participate in the regulation of proliferation, migration, angiogenesis, immune escape, and therapeutic resistance of cancer cells, thus emerging as critical targets for clinical cancer therapy. Compared to HATs, inhibitors of HDAC have been clinically used for cancer treatment. Here, we enumerate and integratethe mechanisms of HDAC family members in tumorigenesis and cancer progression, and address the new and exciting therapeutic implications of single or combined HDAC inhibitor (HDACi) treatment.